Today we recognize #Juneteenth, which commemorates the end of slavery in the United States. While there is much more work to be done, today we reflect on the progress that has been made towards a more inclusive society & our continued commitment to accountability & change.

Did you know? Melanoma, a deadly form of skin cancer, is often more aggressive with NRAS mutations. We're conducting a Phase 1/2 trial for those with RAS-mutated melanoma and other advanced solid tumors: buff.ly/3XfebFU #CancerResearch #StandUpToCancer

Cue the sparkles! Wishing our friends and colleagues a happy 4th of July.

#ICYMI our management team provided a corporate update at the Jefferies Healthcare Conference last month. Watch the webcast to learn about our pipeline of medicines targeting MAPK driven #RAS and #RAF tumors: buff.ly/45fzWqR

We are delighted to host students from local high schools to the Immuneering Summer Internship program, supporting our researchers and helping to develop medicines with broad activity for large populations of cancer patients. Join us in welcoming our newest Immuneers!

Our CSO Brett Hall, PhD, and CBO [email protected] were in San Diego at #BIO2024 last month to meet with #biotech and #pharma leaders and provide an update on our pipeline of universal-RAS/RAF medicines. @IamBiotech

Keep the coffee coming! #ASCO24 was a great opportunity to meet with some of the most influential oncologists and cancer researchers and spread the word about our pipeline of medicines targeting MAPK driven #RAS and #RAF mutant solid tumors.

DKY? #NRAS mutant melanoma is one of the most common and aggressive forms of melanoma, comprising ~20% of total cases. Our IMM-1-104 clinical trial is enrolling people with advanced solid tumors harboring RAS mutations, such as NRAS-mutant #melanoma. buff.ly/3hL4Z5r

Today $IMRX announced that IMM-1-104 has been granted Fast Track designation for the treatment of first-line pancreatic ductal adenocarcinoma (PDAC); providing the potential to accelerate IMM-1-104’s path to U.S. FDA submission for PDAC. buff.ly/3Wrsox9 #PancreaticCancer

We are honored to join LungCancerAmerica in recognition of #WorldLungCancerDay on Thurs Aug 1 to highlight the need for more #LungCancer research. Learn more: buff.ly/3WrPmEE #NSCLC #DrugDiscovery #CancerResearch #WLCD2024

Today we announced our second quarter 2024 financial results and recent corporate highlights. See our press release for details: buff.ly/3LV3iSz

Protect your skin during these last weeks of summer! AAD says excess UV exposure increases skin cancer risk. Our IMM-1-104 clinical trial is enrolling people with advanced solid tumors including NRAS-mutant #melanoma, one of the most aggressive forms. buff.ly/3hL4Z5r

According to American Lung Association, ~20-25% of lung cancer patients have some kind of #KRAS mutation. We’re honored to be advancing important research to support this underserved group of patients, including those with RAS-mutated #NSCLC.

Meet the $IMRX team at the 2024 @morganstanley Annual Global Health Conference! Ben Zeskind will participate in a fireside chat on 9/6 at 10am ET to discuss our universal-RAS program for advanced solid tumors harboring #RASmutations. For more details: buff.ly/3z9hV1L

Our Co-founder and CEO, @benzeskind will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Health Conference on September 6 at 10am ET to discuss our pipeline, platform, and business strategy. For more details, see our press release: buff.ly/3z9hV1L

Meet us in Barcelona at #ESMO24! Our CEO Ben Zeskind, CSO Brett Petersel Hall, Ph.D., and CBO [email protected] will be onsite to discuss our universal-RAS/RAF medicines & will be available for meetings. Learn more: buff.ly/3hL4Z5r

Today we reported positive initial Phase 2a data including complete and partial responses with IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients. Early but encouraging data! Read the full release here: buff.ly/4d4n1Kw

On September 18th, Mallory Morales, our Chief Accounting Officer, will co-lead the Senior Leadership Workshop during the Finance and Accounting for Bioscience Companies Conference in Boston. See the agenda: buff.ly/3Xu45QV

Today on #WorldPatientSafetyDay we stand with patients & healthcare leaders to promote safe & quality healthcare and extend our gratitude to those participating in our clinical trials and clinical research around the world for the betterment of science and health for all.

#ICYMI: our management team provided a corporate update at the Morgan Stanley 22nd Annual Global Health Conference on 9/6, discussing our pipeline, platform, and business strategy. Listen to the webcast replay to learn more about our pipeline: buff.ly/4gbteHo